Tamanho : 5mg
Telefone : +1 850 650 7790
Synonyms:
| Description | Salvianolic Acid C is extracted from the root of Salvia miltiorrhiza, a perennial plant in the genus Salvia. |
| Targets & IC50 | CYP2C8:4.82 μM (Ki), CYP2J2:5.75 μM (Ki) |
| In vitro | METHODS: Human periodontal stem cells hPDLSCs were pretreated with Salvianolic acid C (0-5 mM) for 1 h, then cultured with LPS (1 µg/mL) for 24 h. Cytokines were detected using ELISA kits. RESULTS: Salvianolic acid C treatment significantly inhibited the expression of TNFα, IL-6 and IL-1β in a dose-dependent manner. [1] METHODS: HEK293T cells stably expressing human-ACE2 were treated with Salvianolic acid C (0-100 µM), and viral entry was studied using the SARS-CoV-2 HSCs pseudovirus (PsV) system. RESULTS: Salvianolic acid C inhibited SARS-CoV-2 PsV entry on 293T/ACE2 cells with an IC50 of 3.85 µM.[2] |
| In vivo | METHODS: To investigate the effects on liver injury, Salvianolic acid C (5-20 mg/kg) was intraperitoneally injected into C57BL/6J mice with CCl4-induced hepatic fibrosis once a day for six days, followed by APAP (400 mg/kg) to induce liver injury. RESULTS: Salvianolic acid C protects hepatocytes from APAP-induced injury by attenuating mitochondrial oxidative stress, inflammatory response, and cystatinase-mediated anti-apoptotic effects via inhibition of the Keap1/Nrf2/HO-1 signaling axis. [3] |
| Molecular Weight | 492.43 |
| Formula | C26H20O10 |
| Cas No. | 115841-09-3 |
| Smiles | OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2oc(cc12)-c1ccc(O)c(O)c1 |
| Relative Density. | 1.571g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (111.69 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5.5 mg/mL (11.17 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
